<DOC>
	<DOCNO>NCT02582255</DOCNO>
	<brief_summary>A Phase 4 study evaluate safety immunogenicity monovalent oral polio vaccine type 2 healthy IPV-vaccinated child age 1 5 year Lithuania .</brief_summary>
	<brief_title>A Study Evaluate Safety Immunogenicity Monovalent OPV2 Children Aged 1 5 Years Lithuania</brief_title>
	<detailed_description>Sabin 2 withdrawn routine use globally April 2016 per SAGE recommendation time write protocol . After cessation OPV2 , stockpile mOPV2 maintain potential use necessary response future outbreak . However , risk cVDPV2 Sabin 2 setting low population immunity . Research ongoing develop vaccine genetically stable currently available Sabin 2-containing OPVs . To generate data immunogenicity , safety , genetic stability Sabin 2 vaccine ( mOPV2 ) future comparator new polio vaccine research global switch tOPV bOPV , study mOPV2 perform evaluate safety , immunogenicity ( humoral intestinal ) genetic stability endpoint mOPV2 child age 1 5 year well understand stockpile use vaccine , potential new polio vaccine type 2 component future .</detailed_description>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Polymyxin B</mesh_term>
	<criteria>1 . 1 5 year age , previously vaccinate three four dos IPV . 2 . Healthy without obvious medical condition preclude entry subject study establish medical history physical examination . 3 . Written inform consent obtain 1 2 parent ( ) legal guardian ( ) per country regulation . 1 . Previous vaccination poliovirus outside national immunization schedule . 2 . Any confirmed suspected immunosuppressive know immunodeficient condition include human immunodeficiency virus ( HIV ) infection . 3 . Family history congenital hereditary immunodeficiency . 4 . Major congenital defect serious uncontrolled chronic illness ( neurologic , pulmonary , gastrointestinal , hepatic , renal , endocrine ) . 5 . Known allergy component study vaccine antibiotic . 6 . Administration immunoglobulins and/or blood product since birth plan administration study period . 7 . Acute severe febrile illness day vaccination deem Investigator contraindication vaccination ( child include late time within age window in/exclusion criterion met. ) . 8 . Member subject 's household ( live house apartment unit ) receive OPV last 3 month . 9 . Subject , opinion Investigator , unlikely comply protocol inappropriate include study safety benefitrisk ratio subject .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>